Prostamax

What is Prostamax?

Prostamax is a synthetic short peptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, positioned in the catalog as the prostate-tissue-specific entry. It is most commonly cited as a tetrapeptide with the sequence Lys-Glu-Asp-Pro (KEDP), paralleling the short-sequence naming convention of other Khavinson tissue-targeted peptides (Livagen / KEDA for liver and immune, Vesugen / KED for vasculature, Bronchogen / AEDL for bronchial epithelium, Cardiogen / AED for myocardium). The underlying claim is that Prostamax selectively interacts with prostate tissue and modulates gene expression patterns in aging prostatic epithelial and stromal cells, with proposed applications in benign prostatic hyperplasia (BPH), chronic prostatitis, and age-related decline in prostate function. The peptide is often described as the chemically defined synthesized counterpart to the older natural-extract preparation Prostatilen (also known as Vitaprost), a peptide complex derived from bovine prostate tissue that has a longer Russian clinical registration history. The PubMed-indexed evidence specific to Prostamax as a defined KEDP tetrapeptide is small — primarily Khavinson-group or Russian-collaborator organotypic tissue-culture and gene-expression studies — and independent Western replication is essentially absent. Reliable confirmation of the exact amino acid sequence in peer-reviewed structural literature is limited; the KEDP attribution appears in Khavinson-aligned review material and commercial product listings rather than in a definitive published structural paper, which is itself part of the honest caveat on this peptide.

What Prostamax Is Investigated For

Prostamax is studied within the Khavinson bioregulator framework as the prostate-tissue counterpart to the other organ-specific short peptides (Livagen for liver, Vesugen for vasculature, Cardiogen for myocardium, Bronchogen for bronchial epithelium) and is discussed in biohacking and Russian-language longevity circles for benign prostatic hyperplasia, chronic prostatitis, and age-related prostate function decline. The available peer-reviewed Prostamax-specific evidence is small and concentrated in Russian-language or Russian-authored journals: organotypic tissue-culture work reporting age-dependent stimulation of prostate tissue proliferation, gene-expression studies on prostate cell models, and inclusion in broader Khavinson tissue-specificity reviews. Much of the surrounding clinical folklore is inherited from the older natural-extract preparation Prostatilen (Vitaprost), a bovine prostate peptide complex with a more substantial Russian clinical registration history for BPH and chronic prostatitis, but Prostatilen evidence does not transfer automatically to the synthesized KEDP tetrapeptide. There are no PubMed-indexed randomized controlled trials in humans for Prostamax specifically in any urological indication, no independent Western preclinical replication of the prostate-regeneration claim, and no characterized human pharmacokinetics for the KEDP tetrapeptide. Prostamax is sold as a research chemical or as a Russian-market dietary peptide complex capsule (Peptides.ru / Khavinson Peptides line) depending on the channel, and has no FDA approval, no EMA approval, and no formal registration as a Western prescription medicine.

History & Discovery

Prostamax is the prostate-tissue entry in the Khavinson short peptide bioregulator catalog developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. The methodological template, laid out across decades of Russian-language publications and a smaller set of English-language reviews, was to take tissue-specific complex extracts from animal organs (thymus, pineal, liver, prostate, heart, vasculature, bronchial tissue, and so on), fractionate them to identify putatively active short-peptide components, and then synthesize chemically defined short peptides meant to reproduce the tissue-targeting effect. On the prostate side, the older natural-extract preparation Prostatilen — marketed in Russia as Vitaprost in suppository, injectable, and tablet formulations — was developed first, derived from bovine prostate tissue and used in Russian urology for benign prostatic hyperplasia and chronic prostatitis since the late Soviet and early post-Soviet period. Prostamax occupies the synthesized-Cytogen slot alongside this older Cytomedin preparation and is most commonly identified as the tetrapeptide Lys-Glu-Asp-Pro (KEDP), paralleling the short-sequence naming convention used for its sibling peptides. The PubMed-indexed literature on Prostamax specifically as a defined KEDP tetrapeptide is modest compared to flagship Khavinson entries like Epithalon, Livagen, or Thymalin: organotypic tissue-culture studies of prostate explants in young and old animals, gene-expression work on prostate cell models, and inclusion in broader tissue-specificity and gene-regulation reviews. A substantial amount of the Russian-language clinical evidence that gets cited in Prostamax consumer material actually describes the older Prostatilen extract rather than the synthesized tetrapeptide. Independent Western preclinical replication by urology, structural-biology, or chromatin laboratories has not materialized, and there is no PubMed-indexed Western-standard human clinical trial of the synthesized Prostamax KEDP tetrapeptide for any urological indication. The peptide reaches Western users almost exclusively through research-chemical lyophilized vials labeled 'not for human use' or through the Russian-market Khavinson Peptides / Peptides.ru oral capsule line marketed as a dietary peptide complex — neither of which represents validated therapeutic use, and neither of which is regulated to the evidence standard that would normally accompany a drug for a urological indication.

How It Works

Prostamax is proposed to act as a 'tissue-specific' short peptide that selectively interacts with prostate cells and nudges their gene expression toward a healthier, younger pattern. The idea is that as the prostate ages, genes involved in normal epithelial maintenance and stromal balance become progressively silenced or mis-regulated, contributing to BPH, chronic inflammation, and functional decline. A short peptide with the right sequence is claimed to bind DNA regulatory regions in prostate cells and reactivate or rebalance some of those programs. This is the same general framework the Khavinson program applies to all its tissue-targeted short peptides — the specific details for prostate tissue are considerably less established than for the better-studied members of the catalog.

Within the Khavinson bioregulator framework, Prostamax (cited as Lys-Glu-Asp-Pro) is proposed to act through direct interaction with DNA regulatory regions and histone proteins in prostatic epithelial and stromal cells, modulating chromatin accessibility and gene expression patterns in aging prostate tissue. In organotypic tissue-culture studies from the Khavinson program, prostate explants from aged animals have been reported to respond to the corresponding short prostate peptide with stimulated cell proliferation, which the group interprets as age-dependent reactivation of silenced gene programs — the same pattern reported for Cardiogen in myocardial explants, Livagen in liver explants, and the other tissue-targeted bioregulators in their respective organ cultures. The broader tissue-specificity literature groups Prostamax with Livagen, Vesugen, Cortagen, Bronchogen, and others, claiming each short peptide preferentially activates cells of its named target tissue through sequence-specific DNA recognition — though a concrete molecular mechanism for how a tetrapeptide achieves tissue-specific gene regulation has not been established even within the Khavinson literature and has not been independently validated by Western structural biology or chromatin research. The older parent preparation Prostatilen, a bovine prostate peptide complex, has a more developed preclinical and Russian clinical literature describing anti-edematous, anti-inflammatory, and microcirculation-improving effects in prostate tissue in BPH and chronic prostatitis models. Khavinson-aligned sources frame Prostamax as the chemically defined synthetic fragment responsible for these effects, but the evidence that the KEDP tetrapeptide specifically recapitulates the full Prostatilen activity profile is thin. Human prostate tissue mechanistic data, structural data on the proposed DNA binding, molecular identification of regulated gene sets in prostate cells, and any formal receptor or transporter characterization specific to KEDP are absent. The general Khavinson hypothesis that short peptides cross cell membranes via LAT-family amino acid transporters and interact directly with chromatin is at most a candidate framework, not an independently established mechanism.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Prostamax:

• 01Independent confirmation of the KEDP sequence assignment — a definitive peer-reviewed structural paper specifically assigning Lys-Glu-Asp-Pro to a molecule labeled 'Prostamax' is harder to find than for better-characterized Khavinson peptides (Epithalon, Livagen, Vesugen), and the sequence remains a working consensus rather than fully independently verified fact.
• 02Western-standard human clinical trials — no PubMed-indexed randomized controlled trial of the synthesized KEDP tetrapeptide for BPH, chronic prostatitis, or any other urological indication exists.
• 03Disaggregation from the Prostatilen / Vitaprost evidence base — most of the consumer-facing clinical material cited for Prostamax actually originates from studies of the older bovine prostate peptide extract (Prostatilen), and the synthesized KEDP tetrapeptide has not been shown to recapitulate the parent extract's full activity profile in controlled head-to-head work.
• 04Independent preclinical replication — Western urology and structural-biology laboratories have not reproduced the prostate-selective gene-regulation claims of the Khavinson program.
• 05Receptor or transporter identification — the molecular pathway by which a tetrapeptide would selectively reach prostate epithelial and stromal cells and modulate chromatin in a tissue-specific way has not been established outside the broader Khavinson direct-DNA-interaction hypothesis.
• 06Human pharmacokinetics — oral bioavailability, systemic exposure, tissue distribution to prostate, and elimination of the KEDP tetrapeptide in humans are uncharacterized.
• 07Safety in pre-malignant prostate pathology — the proliferative gene-expression signals reported in Khavinson tissue-culture work raise theoretical concerns about effects in prostatic intraepithelial neoplasia (PIN) or occult prostate cancer that have not been adequately studied even in animal models.
• 08Long-term safety in older male populations — the canonical Khavinson 10-30 day course repeated periodically has not been evaluated for cumulative long-term effects on PSA, prostate volume, or cancer incidence in any controlled human cohort.

Forms & Administration

Prostamax reaches users through two primary channels: Russian-market oral capsules sold as dietary peptide complexes (Peptides.ru / Khavinson Peptides brand line), and Western research-chemical injectable lyophilized powder labeled 'not for human use.' Russian protocols describe short courses (10–30 days) of daily oral capsules repeated periodically. Research-chemical injectable protocols, where used, follow the subcutaneous convention of other Khavinson short peptides at roughly 100–200 mcg per dose, reconstituted in bacteriostatic water. The older parent extract Prostatilen is additionally available in Russia as rectal suppositories, intramuscular injection, and oral tablets under the Vitaprost brand for urological indications, but this is a different preparation with its own registration status and should not be conflated with the synthesized KEDP tetrapeptide. No Western clinician operates a validated Prostamax protocol. All peptides should only be used under the guidance of a qualified healthcare provider — and for any prostate condition, standard urological evaluation and evidence-based pharmacotherapy are dramatically better established than Prostamax. Never self-administer without clinician oversight.

Common Questions

Who Prostamax Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies of Prostamax as a defined KEDP tetrapeptide exist in the indexed clinical literature. Theoretical considerations follow from the proposed prostate-tissue-modulating mechanism and from overlapping pharmacology with standard BPH therapy. Concurrent use with alpha-blockers (tamsulosin, alfuzosin, silodosin, doxazosin) — the first-line BPH pharmacotherapy class — could in principle interact with any peptide-mediated effect on prostatic smooth muscle or stromal compartment, though no data quantify this. Concurrent use with 5-alpha-reductase inhibitors (finasteride, dutasteride) operates on a different mechanism (androgen conversion) and is unlikely to have direct interaction with the KEDP tetrapeptide, but the combined effect on prostatic gene expression has not been studied. PDE5 inhibitors used for BPH (tadalafil) and for erectile dysfunction would not be expected to interact pharmacokinetically with a small dipeptide. The bigger practical concern is that Prostamax use without urology oversight could obscure clinical signals (urinary symptom evolution, PSA changes) that should drive evidence-based clinical decision-making. Any concurrent prescription medication for prostate or urological conditions should be disclosed to the prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions